Disseminated BCG following intravesical therapy for transitional cell carcinoma, report of two cases

Lama Zakarneh, Rola Salama, Nayef Aqel


Intravesical vaccination by BCG has proved to be an effective immunotherapy of superficial transitional cell carcinoma (TCC) of the urinary bladder. It is useful in slowing down of the tumour progression and improves patients’ survival. Its side effects include local urinary symptoms and mild general side effects. Serious systemic complications of intravesical BCG immunotherapy are rare. We describe two patients who developed dissemination of BCG following intravesical instillation for the treatment of bladder TCC.

Full Text:



  • There are currently no refbacks.